Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Trading Down 5.8 %

Shares of NASDAQ:GLMD opened at $3.87 on Friday. The business has a fifty day simple moving average of $3.60 and a 200 day simple moving average of $4.05. Galmed Pharmaceuticals has a 1 year low of $2.73 and a 1 year high of $10.50. The firm has a market cap of $2.48 million, a price-to-earnings ratio of -1.61 and a beta of 0.67.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.